DUBLIN, March 9, 2020 /PRNewswire/ -- The "Disease Analysis: Type 1 Diabetes" report has been added to ResearchAndMarkets.com's offering.
Research and Markets Logo
The research estimates that in 2018, there were approximately 46.6 million prevalent cases of type 1 diabetes in adults aged 20 years and over worldwide, and forecasts that number to increase to 51.8 million prevalent cases by 2027.
In children and adolescents aged below 20 years, there were approximately 1.08 million prevalent cases of type 1 diabetes worldwide in 2018, which are expected to increase to 1.12 million prevalent cases by 2027.
The overall likelihood of approval of a Phase I type 1 diabetes asset is 16.3%, and the average probability a drug advances from Phase III is 73.9%. Type 1 diabetes drugs, on average, take 8.5 years from Phase I to approval, which is the same as the average duration to approval in the overall endocrine space.
Despite the presence of multiple well-established products, the type 1 diabetes market is expected to see limited growth over the next decade. Future growth opportunities in the type 1 diabetes market are expected to be limited by its saturation with multiple maturing insulins, pricing pressures following the launches of biosimilars, and the expected failure of sodium-glucose cotransporter-2 (SGLT-2) inhibitors to gain approval in the lucrative US market.
It is expected that patients will continue to switch from Novo Nordisk's Levemir to its successor product Tresiba due to the company's promotion of Tresiba's longer duration of blood sugar control compared to Levemir.
Likewise, Sanofi is pursuing a comparable commercial strategy to Novo Nordisk by promoting its next-generation insulin glargine product Toujeo over Lantus, as Lantus continues to lose patient share to the more affordable biosimilar Basaglar. However, key opinion leaders interviewed by the research analysts suggest that physicians are unconvinced that Toujeo possesses tangible benefits over biosimilar insulin glargine to justify its higher price.
Payers are severely restricting the use of specific insulin brands in the US. As the list price of insulins continues to increase, cost is becoming a strong determining factor for the choice of insulin treatment. Interviewed endocrinologists emphasized the impact of pricing on prescribing trends, as price fluctuations in the US lead to regular switching among patients.
Tresiba is forecasted to see the greatest uptake of all the long-acting insulin therapies in type 1 diabetes. Its long-acting duration of 42+ hours and its flexible dosing window (it can be administered at different times each day) offer improved convenience for patients, along with strong glycated hemoglobin (HbA1c) reductions. In addition, favorable pricing compared to Lantus and Toujeo within the US market is expected to drive growth of Novo Nordisk's market share.
The maturation of multiple short-acting insulin products has resulted in companies promoting switching to successor products with extended patent protection to maintain their diabetes revenues. Novo Nordisk's NovoLog will be facing biosimilar competition from Sanofi's SAR341402, therefore Novo Nordisk is actively encouraging patients to switch to NovoLog's successor ultra-rapid product Fiasp, which is positioned as having a faster onset of activity than NovoLog. Similarly, Eli Lilly has developed a faster-acting version of Humalog, ultra-rapid lispro, which is currently in preregistration in the US.
Increasing out-of-pocket costs for patients and competition from Sanofi's Admelog (a biosimilar of Humalog) have resulted in developers of branded products launching authorized generics in order to increase competitiveness in US government-insured patients, who must make co-payments based on a percentage of a drug's list price. In May 2019, Eli Lilly launched an authorized generic of Humalog at 50% of the list price of branded Humalog in hopes of maintaining government-insured patient share. This was followed in January 2020 by Novo Nordisk's launch of an authorized generic version of NovoLog, also at a 50% discount to the branded product.
Pipeline product teplizumab has shown promising potential to prevent or delay the onset of type 1 diabetes, as Phase II data have demonstrated that a single course of the drug significantly delayed disease onset in at-risk patients by a median of two years. The data will support a planned rolling Biologics License Application (BLA) submission for the prevention or delay of type 1 diabetes in H1 2020, and the review process will be fast tracked due to breakthrough therapy designation granted by the US Food and Drug Administration (FDA). However, if approved, teplizumab is likely to face two challenges when attempting to enter the market, the first of which is appropriately pricing the product to reflect the market value of delaying or preventing diabetes while ensuring that a high upfront cost does not prevent reimbursement. Indeed, achieving widespread reimbursement will be particularly challenging given the lack of a currently approved comparator and the fact that the mean duration of any delay in the onset of diabetes may not be known at the time of approval. The second challenge is the lack of existing screening programs to detect patients that are at risk for type 1 diabetes, which could severely limit the drug's target population (at least initially). Teplizumab's commercial success will therefore require healthcare services, physicians, and industry to collaborate on creating and integrating accessible screening programs into different health services globally.
Lexicon continues to pursue first-to-market status for Zynquista for type 1 diabetes in the US, and launched an appeal against the FDA's initial complete response letter (CRL), but this was unsuccessful. Thus, the company has now appealed to the Center for Drug Evaluation and Research, and is expecting a final judgment to be made in February 2020, but we expect this will also fail given that no new trial data have been added to the NDA to allay safety concerns and Lexicon has stated it does not wish to initiate further studies. An FDA decision on Jardiance's supplementary New Drug Application (sNDA) is expected in late Q1/early Q2, but a rejection is widely expected given the Endocrinologic and Metabolic Drugs Advisory Committee panel voted 14-2 against approval in November 2019. While SGLT-2 inhibitors may offer benefits to type 1 diabetes patients beyond improved glycemic control (namely blood pressure reduction and weight loss), our base case is that the class will not gain FDA approval for type 1 diabetes without additional studies to further investigate the risk of diabetic ketoacidosis (DKA) and the effectiveness of proposed risk-management strategies, and thus far none of the companies have publicly announced any intention to conduct such studies.
Key Topics Covered:
1. OVERVIEW
Story continues
2. DISEASE BACKGROUND
3. TREATMENT
4. EPIDEMIOLOGY
5. MARKETED DRUGS
6. PIPELINE DRUGS
7. KEY REGULATORY EVENTS
8. PROBABILITY OF SUCCESS
9. LICENSING AND ASSET ACQUISITION DEALS
10. CLINICAL TRIAL LANDSCAPE
11. DRUG ASSESSMENT MODEL
12. MARKET DYNAMICS
13. FUTURE TRENDS
14. CONSENSUS FORECASTS
15. RECENT EVENTS AND ANALYST OPINION
16. KEY UPCOMING EVENTS
17. KEY OPINION LEADER INSIGHTS
18. UNMET NEEDS
19. BIBLIOGRAPHY
20. APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/b9zitm
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/2020-disease-analysis-on-type-1-diabetes---licensing-and-asset-acquisition-deals-301019775.html
SOURCE Research and Markets
Continued here:
2020 Disease Analysis on Type 1 Diabetes - Licensing and Asset Acquisition Deals - Yahoo Finance
- 1 woman thought she was destined for diabetes. This 1 realization helped her lose 70 pounds - Yahoo! Voices - March 29th, 2024
- Franciscan Health offering diabetes education at local churches - The Times of Northwest Indiana - March 29th, 2024
- For diabetes patients, needle-free insulin injections are on the way - ScienceBlog.com - March 29th, 2024
- Las Vegas nonprofit hosting health workshop specifically aimed at local Latinos - KTNV 13 Action News Las Vegas - March 29th, 2024
- How Often Do You Really Need to Check Your Blood Sugar Levels? - WSJ - The Wall Street Journal - March 29th, 2024
- Unintended Effects of Caps on Insulin Out-of-Pocket Costs - Managed Healthcare Executive - March 29th, 2024
- Study: Pompe treatment Nexviazyme isn't linked to new or worsening... - Pompe Disease News - March 29th, 2024
- A Smoker With New-Onset Pain in Both Feet - Medscape Reference - March 29th, 2024
- Pre-diabetes leads to Type 2 diabetes; Here's how to prevent and reverse it - WXII12 Winston-Salem - March 29th, 2024
- 'From Interpretation to Action': Using CGM to Manage T2D - Medscape - March 29th, 2024
- March: diabetes-kidney | News and features - University of Bristol - March 29th, 2024
- Health centers attempt to prevent diabetes - WTVM - March 29th, 2024
- Beyond Meat Unveils New and Expanded Line of Beyond Crumbles, Now Certified by the American Heart ... - Yahoo Finance - March 29th, 2024
- Beyond Meat Launches Revamped Plant-Based Crumbles, Earning American Heart and Diabetes Association ... - vegconomist - the vegan business magazine - March 29th, 2024
- Ypsomed hands off insulin pen needle business to focus on smart pump, autoinjector development - Fierce Biotech - March 29th, 2024
- Take the online diabetes test that could help save your life - NBC Connecticut - March 29th, 2024
- Study evaluates the use of tirzepatide in overweight/obese adults with type 1 diabetes - News-Medical.Net - March 29th, 2024
- Risk prediction using genes and gut bacteria can improve early detection of diseases like type 2 diabetes - Medical Xpress - March 29th, 2024
- On a Healthy Vegan Diet, I've Healed My Liver, Reversed Type 2 Diabetes, and Lost 35 Pounds - Forks Over Knives - March 29th, 2024
- Study Links Diet, Diabetes, and Alzheimers - Neuroscience News - March 29th, 2024
- Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be - Yahoo Finance - March 18th, 2024
- Doctor warns of strange telltale sign of diabetes which can appear on the legs - The Mirror - March 18th, 2024
- Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies - News-Medical.Net - March 18th, 2024
- Popular diabetes and weight loss drugs often hard to get for people who need them - NBC News - March 18th, 2024
- Your Health Matters: The ABCs of diabetes - The Globe | News, weather, sports from Worthington, Minnesota - The Globe - March 18th, 2024
- The Link Between Pancreatic Cancer and Diabetes - Cedars-Sinai - March 18th, 2024
- Nikita Kuzmin diabetes: what was he holding in the CBB house? - Cosmopolitan UK - March 18th, 2024
- FDA Approves Rezdiffra, the First Drug for Diabetes-Related Liver Disease - diaTribe Foundation - March 18th, 2024
- He took up running rather than take diabetes medication. It worked - South China Morning Post - March 18th, 2024
- Can Eating Yogurt Really Reduce Your Risk of Diabetes? - Health.com - March 18th, 2024
- Even short periods of diabetes remission are linked to lower risk of heart attack and stroke - The BMJ - March 18th, 2024
- Kidney stone risk factors and how type 2 diabetes medication may help - WECT - March 18th, 2024
- 'Making the Invisible Visible': CGMs Offer Insights for T2D - Medscape - March 18th, 2024
- Novo Nordisk Discontinues Insulin Medication After Cutting Its Price - The American Prospect - March 18th, 2024
- Infographic: Where GLP-1s Work Now -- and What's Coming - Medscape - March 18th, 2024
- Intermountain Health Experts Say Education Key to Prevention of Type 2 Diabetes | PRUnderground - PR Underground - March 18th, 2024
- International body recommends more sensitive test to indicate risk of developing diabetes - The Hindu - March 18th, 2024
- The importance of knowing your A1C level - KSAT San Antonio - March 18th, 2024
- Tandem Diabetes Care's t:slim X2 Insulin Pump is the First Automated Insulin Delivery System to Integrate with ... - Business Wire - January 9th, 2024
- Diffuse Alveolar Hemorrhage Occurring Suddenly in a Diabetic Patient With Asthma Exacerbation - Cureus - January 9th, 2024
- Virginia Tech researchers find drugs used to treat Type 2 diabetes reduce alcohol cravings - WRIC ABC 8News - January 9th, 2024
- FDA looking into reports of hair loss, suicidal thoughts in people using popular drugs for diabetes and weight loss - CNN - January 9th, 2024
- Glycemic control and cardiovascular outcomes in patients with diabetes and coronary artery disease according to ... - Cardiovascular Diabetology - January 9th, 2024
- Insulin price cap: More Americans will now pay no more than $35 - USA TODAY - January 9th, 2024
- Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for cosmetic reasons instead of for diabetes and obesity - Fortune - January 9th, 2024
- No Increased Risk of Suicidal Ideation With GLP-1 Drugs - Medpage Today - January 9th, 2024
- Ask the Doctors | New research being conducted to treat diabetes - Eureka Times-Standard - January 9th, 2024
- Salivary Chloride Intracellular Channel 1 (CLIC1) as a Hub of Gene-Gene Interactome of Periodontitis With Diabetes ... - Cureus - January 9th, 2024
- Why Omada's CEO Thinks Amazon Selected His Startup as the 1st Partner for Its New Program - MedCity News - January 9th, 2024
- Researchers find drugs used to treat type 2 diabetes and obesity reduce alcohol cravings - Medical Xpress - January 9th, 2024
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different ... - Nature.com - January 9th, 2024
- CV Safety Profile of TheracosBio's BRENZAVVY (bexagliflozin) Confirmed in Research Published in Diabetes ... - Business Wire - January 9th, 2024
- 6 "Bad" Fruits You Should Be Eating When You Have Diabetes, According to Dietitians - EatingWell - January 9th, 2024
- Children of Women with Type 1 Diabetes Have Increased Heart Defect Risk - Inside Precision Medicine - January 9th, 2024
- Transforming Corporate Health: Fitterfly's Success in Tackling Diabetes and Weight Issues - Business Standard - January 9th, 2024
- Ozempic and weight loss | News and views - Diabetes UK - January 9th, 2024
- Drugs used to treat Type 2 diabetes reduce alcohol cravings - ScienceBlog.com - January 9th, 2024
- People taking Wegovy and Ozempic have lower risk of suicidal thoughts vs. older drugs, study finds - ABC News - January 9th, 2024
- For Those With Diabetes On Medicare Part D, Insulin Is $35...If Its Covered - Forbes - October 27th, 2023
- Biologist Douglas Melton: I was studying frogs until my son was diagnosed with diabetes then I started looking for a cure - EL PAS USA - October 27th, 2023
- Diabetes and Hearing Loss with Concept by Iowa Hearing | Paid Content - Local 5 - weareiowa.com - May 9th, 2023
- COUNTY COLUMN: Learn to Live well with diabetes at The Well - Norman Transcript - May 1st, 2023
- Want to Cut Type 2 Diabetes Risk? This High-fat Food Can Be the Answer, According to New Study - Revyuh - May 1st, 2023
- Diabetes: What It Is, Causes, Symptoms, Treatment & Types - March 13th, 2023
- A number of healthtech startups claim they can reverse Type 2 diabetes. But caveats apply, caution doctors - Economic Times - March 13th, 2023
- Tampa doctor who lost brother to diabetes calls insulin price cut a 'game changer' - ABC Action News Tampa Bay - March 5th, 2023
- New study suggest people previously infected with COVID-19 could have increased risk for diabetes - CBS Los Angeles - February 16th, 2023
- Diabetes Symptoms, Causes, & Treatment | ADA - October 15th, 2022
- A nutritionist with type 1 diabetes shares the top 5 'food swaps' she eats to manage her blood sugar - CNBC - October 15th, 2022
- Diabetes and the gut: How a bacterial protein may impact insulin - Medical News Today - October 15th, 2022
- Milton teen involved in launch of diabetes support program - Milton Daily Standard - October 15th, 2022
- Providers Now Have Free Access to Latest Diabetes Technology in One Place - PR Newswire - October 15th, 2022
- 5 Modifiable Factors in Women with History of Gestational Diabetes Mellitus That Can Reduce the Risk of T2D - Pharmacy Times - October 15th, 2022
- BCMH the stoy of Diabetes and Determination - 921News - October 15th, 2022
- Can skipping a meal lead to diabetes and fat around abdomen? - The Indian Express - October 15th, 2022
- Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 -... - October 15th, 2022
- Diabetes: Symptoms, risks, and prevention - Wilmington News Journal, OH - July 17th, 2022
- Diabetes symptoms: The sign of nerve damage that often strikes at night - severe - Express - July 17th, 2022
- Local Teen Brings Smiles and Health Kits to Kids with Diabetes - River Journal Staff - July 17th, 2022
- Type 3 diabetes: symptoms, causes and treatments - Livescience.com - July 17th, 2022